GSK's B7─H3─targeted ADC, GSK'227, receives EMA PRIME designation in relapsed extensive─stage small─cell lung cancer
GSK plc announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) Designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for the treatment of patients with relapsed extensive- …